Making a difference for traumatic brain injury patients
Emerging new Company veriNOS pharmaceuticals, established in October 2022, Led by CEO, Christian Wandersee and CMO Professor John Stover, provides an update on its revival of late-stage drug candidate ronopterin for the treatment of Traumatic Brain Injury (TBI).
Ronopterin is the first and only iNOS inhibitor which has demonstrated repeated signs of neuroprotection in TBI patients following data from its two late-stage clinical trials. veriNOS are pursuing the drug’s potential, following strong evidence that the early start of infusion is the pathway forward in future trials and has the potential to improve the standard of care for TBI patients.
Beyond TBI, the company will also be looking to use ronopterin in oncology and ophthalmology.
CEO, Christian Wandersee and CMO Professor John Stover, spoke with Richard Staines, Account Director at Optimum Strategic Communications about the Company’s aim and focus moving forward.
Read the article in Pharmaphorum here.